Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
LLS Continues to Drive Progress to Cancer Cures
(Rye Brook, NY, Jan. 15 2019) – Groundbreaking advances that harness the body’s immune system to attack cancer cells are set to continue, as well as significant focus on new therapies for children with cancer. And expect the revolution to gain steam in cancer treatments moving away from toxic chemotherapy toward genetics-driven targeted therapies, the foundation of precision medicine. This according to L...
U.S. Senate Introduces Cancer Drug Parity Act
Washington, DC (December 12, 2018) – The Leukemia & Lymphoma Society (LLS) is proud to support the Cancer Drug Parity Act, which will ensure equality of insurance coverage for all cancer treatments, regardless of how these treatments are administered. This bipartisan legislation was introduced today in the U.S. Senate by Senator Tina Smith (D-Minn.), Senator Jerry Moran (R-Kan.), Senator Chris Murphy (D-Conn.) ...
Burlington Stores Raises More Than $37M For The Leukemia & Lymphoma Society
(RYE BROOK, N.Y., Dec. 4, 2018) – Burlington Stores and The Leukemia & Lymphoma Society (LLS) joined forces for the 17th consecutive year to help save lives and bring smiles to those touched by blood cancer. From September 9 through December 1, Burlington's more than 670 locations nationwide encouraged customers to donate $1 or more at checkout to support LLS's goal to create a world without blood cancer. This ...
LLS Releases Results of its Precision Medicine Trial in Deadly Leukemia at ASH
View full release here. SAN DIEGO, CA (Nov. 30, 2018) – The Leukemia & Lymphoma Society (LLS) continues to deliver on its promise to “Beat AML,” the deadliest of the blood cancers, through its groundbreaking Beat AML® Master Clinical Trial, a precision medicine approach to treating these cancer patients. The first results of this trial, to be announced Sunday and Monday at the 60th Amer...
LLS Fuels Next Generation of Cancer Research Committing $188 Million
View full multimedia release here. Rye Brook, NY (November 8, 2018) - Driving the dizzying pace of breakthroughs in blood cancer treatments, The Leukemia & Lymphoma Society (LLS) announced today $42 million for 80 blood cancer research teams around the world. This latest infusion of funding by LLS, the world’s largest nonprofit devoted to curing blood cancers, brings the organization’s current com...
New Study Demonstrates Burdensome Cost of Blood Cancer Care
Rye Brook, NY (Oct. 29, 2018) – The costs to treat a blood cancer are higher than costs for other cancers, and the costs incurred by a patient diagnosed with a blood cancer do not return to pre-cancer levels, according to a Milliman study commissioned by The Leukemia & Lymphoma Society (LLS). Released today, this study—The Cost Burden of Blood Cancer Care—offers new information on the cost of blood can...
LLS Receives Significant Gift to Support Promising Young Scientists
(Rye Brook, NY, October 10, 2018) –The Leukemia & Lymphoma Society (LLS) continues to lead cutting-edge research to advance treatments for myeloma and lymphoma. Adding to the momentum, the organization today announced a $1,175,000 commitment by the Schwartz Ward Family Foundation (SWFF) of Chicago to support two unique research initiatives including a novel therapy for a rare form of lymphoma and an innovative ...
Patient Groups File Amicus Brief Challenging Short-Term Health Insurance Rule
RULE COULD RESULT IN COMPREHENSIVE COVERAGE FOR PATIENTS BECOMING UNAFFORDABLE; LEAVE MANY UNCOVERED Patient groups representing millions of Americans with serious health conditions filed an amicus curiae (or friend-of-the-court) brief today in the U.S. District Court case, Association for Community Affiliated Plans v. United States, explaining the devastating impact patients could face under the fi...